ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1298

Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort

Maria Schletzbaum1, Nnenna Ezeh2, Trevor McKown3, Shivani Garg4 and Christie Bartels5, 1University of Wisconsin-Madison School of Medicine and Public Health, Department of Population Health Sciences, Madison, WI, 2University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, 3William S. Middleton Memorial Veterans Hospital, Madison, WI, 4UW Madison, Madison, WI, 5University of Wisconsin School of Medicine and Public Health, Department of Medicine, Division of Rheumatology, Madison, WI

Meeting: ACR Convergence 2020

Keywords: Aging, Damage Index, Disparities, longitudinal studies, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: While medical comorbidities increase with age, younger age at onset of Systemic Lupus Erythematosus (SLE) has been associated with greater risk of some types of end-organ damage. Few studies have reported damage-free survival by age at diagnosis which would be useful for prognosis discussions. Using a large single-center retrospective cohort of incident SLE patients, the objectives of this study were to estimate new damage and mortality-free median survival time and 1-, 5-, and 10-year survival probabilities and to compare damage-free survival by age at diagnosis and within organ systems.

Methods: Electronic Health Records (EHR) from a single academic health system were queried for patients with SLE diagnosis codes in 2003-2016 and at least one visit to both a rheumatology and a primary care provider to better capture damage events. Trained abstractors manually validated cases meeting either 1997 ACR or 2012 SLICC SLE criteria and recorded damage event dates, including events pre-EHR. Age at diagnosis used the earliest date of a SLE diagnosis code from a rheumatologist or date of meeting SLE criteria. Patients with less than 30 days of observation after diagnosis were excluded.

All observed events within the post-diagnosis follow-up period were compared by age group at diagnosis (< 30, 30-44, 45-59, and 60+ years). Gross damage rates were calculated using Poisson regression. Kaplan-Meier was used to estimate new damage and mortality-free median survival time and 1-, 5-, and 10-year survival probabilities by age group at diagnosis. Differences in organ-specific damage-free survival by age group at diagnosis were assessed with logrank tests on Kaplan-Meier curves.

Results: The cohort included 462 patients with incident SLE followed for a median of 6 years. There were 86 (19%) patients diagnosed before age 30, and the median diagnosis age was 45 (Table 1). Patients diagnosed before age 30 were more likely to be Asian, Black or to receive Medicaid. Of SLE damage events observed after diagnosis, the most common were neuropsychiatric (18% of events), ocular (17%), and musculoskeletal (14%). Increasing age group correlated with gross damage rate, from 10% per year risk in those < 30, to 39% per year risk in those 60+ (Table 2). Survival until first damage event after diagnosis was similar in patients diagnosed before age 30 and ages 30-44; survival decreased in older age groups. In the first year, patients younger than 30 years experienced damage rates similar to older age groups (45-59 year olds) (Figure 1). For most organ systems, survival without damage negatively correlated with age. However, cardiovascular and pulmonary damage-free survival was similar or shorter in patients diagnosed < 30 compared to those diagnosed decades later in life.

Conclusion: Younger patients (< 30), who were more likely to be non-White and Medicaid beneficiaries, experienced a relatively high rate of first damage in the first year after diagnosis and similar damage rates to patients decades older within cardiovascular and pulmonary systems. Overall damage rates in SLE correlated with age at diagnosis, with a 30% per year difference in damage risk between the youngest (< 30) and oldest ( >60) patients at SLE diagnosis.

Figure 1. Damage, Cardiovascular, and Pulmonary Damage-Free Survival by Age Group at Diagnosis. Kaplan-Meier survival curves for damage after lupus diagnosis by age group at diagnosis with death as a censoring event for select organ systems. Panel A shows survival until first new damage event after diagnosis. Survival time was longer in patients diagnosed before age 45 and decreased with increasing age group. Panel B shows cardiovascular damage-free survival, which was longer for patients diagnosed before 45 compared to those after age 60. Panel C displays pulmonary damage-free survival which was shorter for patients diagnosed after age 60 than those diagnosed younger.


Disclosure: M. Schletzbaum, None; N. Ezeh, None; T. McKown, None; S. Garg, None; C. Bartels, Independent Grants for Learning and Change (Pfizer), 2.

To cite this abstract in AMA style:

Schletzbaum M, Ezeh N, McKown T, Garg S, Bartels C. Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/lupus-damage-free-survival-by-age-at-diagnosis-a-retrospective-incident-lupus-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/lupus-damage-free-survival-by-age-at-diagnosis-a-retrospective-incident-lupus-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology